ライフサイエンスコーパス: quadrivalent

1 (26/50) revealed a classical fully synapsed quadrivalent.

2 with the X-Y bivalent to form trivalents and quadrivalents.

3 r-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine.

4 Only 2 participants harbored a quadrivalent (4vHPV)-targeted genotype (0.5% [95% CI, .1

5 The quadrivalent A/C/Y/W-135 meningococcal polysaccharide va

6 ks and 7 months following vaccination with a quadrivalent (A/C/Y/W-135) polysaccharide vaccine.

7 Quadrivalent adjuvanted inactivated influenza vaccine (a

8 ination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vac

9 irus-associated anogenital disease with both quadrivalent and bivalent vaccines.

10 The quadrivalent and divalent vaccines are compared, particu

11 ed patients had received ccIIV4/Flucelvax(R) Quadrivalent and FluLaval(R) Quadrivalent IIV4, respecti

12 papillomas and has been included in both the quadrivalent and nonavalent prophylactic HPV vaccines.

13 the lifetime health benefits for bivalent or quadrivalent and nonavalent vaccination of 9-year-old an

14 00 vaccinated girls for both the bivalent or quadrivalent and nonavalent vaccines, compared with prev

15 ctions which can be prevented with bivalent, quadrivalent, and nonavalent vaccines was 5.9, 27.1, and

16 dose (SD) quadrivalent (IIV4), cell-based SD quadrivalent (cIIV4), and recombinant quadrivalent (RIV4

17 ures of clade C Env trimers and found that a quadrivalent cocktail of clade C trimers elicited a grea

18 vaccine group) or two doses of meningococcal quadrivalent conjugate vaccine (control group) administe

19 d routine immunization of adolescents with a quadrivalent conjugate vaccine (MenACWY) for the prevent

20 Quadrivalent conjugate vaccines targeting the A, C, W, a

21 A 'quadrivalent' conjugate vaccine against meningococcal se

22 The efficacy of the recently approved quadrivalent CYD-TDV dengue vaccine against asymptomatic

23 uch as immunoglobulin G (IgG) because of its quadrivalent domains that bind to the Fc region of these

24 RIV4) induce a higher antibody response than quadrivalent egg-based inactivated influenza vaccines (I

25 influenza vaccine (cell-cultured, egg-based quadrivalent; egg-based high-dose, adjuvanted, or standa

26 We developed a quadrivalent formulation of VesiculoVax that contains re

27 ere not exclusively protective, the combined quadrivalent formulation protected mice from all challen

28 lgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days

29 mbE-IDMS and SRID in the four strains of the quadrivalent formulation, highlighting the method's stab

30 onal influenza vaccines are transitioning to quadrivalent formulations including the hemagglutinins o

31 We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B

32 We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection an

33 omavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and

34 ndividual-level data on vaccination with the quadrivalent HPV (qHPV) vaccine at 16 years or younger,

35 and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine.

36 lected for the efficacy determination of the quadrivalent HPV (type 6, 11, 16, and 18) L1 virus-like

37 lected for the efficacy determination of the quadrivalent HPV (type 6, 11, 16, and 18) L1 virus-like

38 assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HI

39 hronic oral papillomas with resolution after quadrivalent HPV vaccination and perform a review of the

40 sed by HPV-32 with complete resolution after quadrivalent HPV vaccination and reviewed reports of res

41 ver, data to inform the relationship between quadrivalent HPV vaccination and the subsequent risk of

42 Quadrivalent HPV vaccination during pregnancy was not as

43 omized clinical trials to assess efficacy of quadrivalent HPV vaccination for treatment of oral squam

44 Quadrivalent HPV vaccination of MSM via GUM clinics is l

45 here were 4127 female patients who initiated quadrivalent HPV vaccination or had their first missed H

46 Swedish girls and women 10 to 30 years old, quadrivalent HPV vaccination was associated with a subst

47 To determine whether quadrivalent HPV vaccination would affect the developmen

48 described cases of wart resolution following quadrivalent HPV vaccination.

49 nated, recurrent warts with resolution after quadrivalent HPV vaccination.

50 We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18)

51 ars who had previously completed a series of quadrivalent HPV vaccine (4vHPV), a strategy we refer to

52 Overall, the prevalence of penile quadrivalent HPV vaccine (4vHPV)-type HPV was similar in

53 ly vaccinated with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 year

54 ed to either two doses or three doses of the quadrivalent HPV vaccine (Gardasil [Merck Sharp & Dohme,

55 We studied the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithe

56 By preventing HPV infection, quadrivalent HPV vaccine (qHPV) reduces risk of anal can

57 dose of both bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV).

58 These data support vaccination with quadrivalent HPV vaccine across a broad range of baselin

59 s diagnosed in 19 women who had received the quadrivalent HPV vaccine and in 538 women who had not re

60 The quadrivalent HPV vaccine appears safe and highly immunog

61 s) were randomized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261)

62 Each patient received 3 doses of the quadrivalent HPV vaccine at 0, 2, and 6 months in 2013,

63 Intramuscular injection of 3 doses of quadrivalent HPV vaccine delivered on a standard dosing

64 Quadrivalent HPV vaccine immunogenicity delivered on 3 a

65 o determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening

66 t few data exist regarding the safety of the quadrivalent HPV vaccine in this context.

67 Women received quadrivalent HPV vaccine or placebo (1:1) at entry, week

68 12,343 subjects 9-26 years old randomized to quadrivalent HPV vaccine or placebo in phase 2/3 studies

69 Quadrivalent HPV vaccine prevents infection with HPV-6,

70 mary efficacy objective was to show that the quadrivalent HPV vaccine reduced the incidence of extern

71 He received the quadrivalent HPV vaccine resulting in clearance of all l

72 nated or received one, two or three doses of quadrivalent HPV vaccine six years earlier.

73 The quadrivalent HPV vaccine targeted at types 6, 11, 16, an

74 antly more frequent among subjects receiving quadrivalent HPV vaccine than among those receiving plac

75 aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this ana

76 r age groups revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16,

77 In this study, 1 or 2 doses of quadrivalent HPV vaccine was associated with substantial

78 In this study, 1 or 2 doses of quadrivalent HPV vaccine was associated with substantial

79 The immunogenicity of quadrivalent HPV vaccine was comparable among subjects w

80 With the updated model, the bivalent or quadrivalent HPV vaccine was estimated to avert 15 cases

81 In matched analyses, exposure to the quadrivalent HPV vaccine was not associated with signifi

82 The quadrivalent HPV vaccine was well tolerated by both pati

83 has condyloma or HPV-6/11 infection with the quadrivalent HPV vaccine will result in a high neutraliz

84 ma risk was seen after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was

85 ) according to timing and number of doses of quadrivalent HPV vaccine.

86 ew SCCs and BCCs after the first dose of the quadrivalent HPV vaccine.

87 ed in 2 patients after administration of the quadrivalent HPV vaccine.

88 Bivalent and quadrivalent HPV vaccines protect against 66% of HPV-ass

89 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and

90 Bivalent and quadrivalent HPV vaccines were licensed in the country i

91 We detected quadrivalent (HPV 6/11/16/18) vaccine-preventable types

92 aged 16-26 years were randomised to receive quadrivalent HPV6/11/16/18 vaccine (n=9087), its HPV16 v

93 d at 17 US sites for a clinical trial of the quadrivalent (HPV6,11,16,18) HPV (qHPV) vaccine.

94 In Australia, high uptake of the quadrivalent human papillomavirus (4vHPV) vaccine has le

95 who were enrolled in the phase 3 trials of a quadrivalent human papillomavirus (HPV) 6/11/16/18 vacci

96 The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major pa

97 Immune response to quadrivalent human papillomavirus (HPV) vaccine delivere

98 l designed to compare three and two doses of quadrivalent human papillomavirus (HPV) vaccine in adole

99 The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in preve

100 d by 2 different delivery strategies for the quadrivalent human papillomavirus (HPV) vaccine in Tanza

101 The quadrivalent human papillomavirus (HPV) vaccine is recom

102 We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infec

103 is study was to determine whether the 3-dose quadrivalent human papillomavirus (HPV) vaccine series (

104 The quadrivalent human papillomavirus (HPV) vaccine was lice

105 First generation bivalent and quadrivalent human papillomavirus (HPV) vaccines have be

106 Recent evidence shows that quadrivalent human papillomavirus (qHPV) vaccination in

107 Effectiveness of the quadrivalent human papillomavirus (QHPV) vaccine against

108 In Norway, single-cohort vaccination with quadrivalent human papillomavirus (qHPV) vaccine targeti

109 he Food and Drug Administration licensed the quadrivalent human papillomavirus (types 6, 11, 16, and

110 schedule (administered at 0 and 6 months) of quadrivalent human papillomavirus vaccine (4vHPV) with a

111 V4/Flucelvax(R) Quadrivalent and FluLaval(R) Quadrivalent IIV4, respectively, VE against influenza fo

112 ceived Fluarix(R) Quadrivalent or Fluzone(R) Quadrivalent IIV4, respectively, VE against influenza wa

113 valent (aIIV3), egg-based standard dose (SD) quadrivalent (IIV4), cell-based SD quadrivalent (cIIV4),

114 itu hybridization (FISH) analysis of meiotic quadrivalents in 16 single and 2 double translocation he

115 FISH analysis showed only quadrivalents in all 100 metaphase I nuclei.

116 determined the effectiveness of trivalent or quadrivalent inactivated influenza vaccine (IIV) among s

117 fluenza vaccine (RIV4) or standard egg-based quadrivalent inactivated influenza vaccine (IIV4).

118 uated the efficacy of a cell-culture-derived quadrivalent inactivated influenza vaccine (IIV4c) using

119 ed controlled trial of 2 doses of adjuvanted quadrivalent inactivated influenza vaccine (QIV) versus

120 nt seasonal influenza (>=65 years: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50

121 fluenza vaccine, compared with standard-dose quadrivalent inactivated influenza vaccine, did not sign

122 High-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine, with revacci

123 tiveness (VE) of egg- and cell-culture based quadrivalent inactivated influenza vaccines (IIV4/ccIIV4

124 The uptake of quadrivalent inactivated influenza vaccines was not asso

125 nfluenza of both egg- and cell culture-based quadrivalent inactivated influenza vaccines, with simila

126 olgus macaques were primed with the clinical quadrivalent inactivated virus (QIV) vaccine.

127 In the 2017-2018 influenza season, quadrivalent, inactivated cell-derived influenza vaccine

128 cine (RIV4) with a standard-dose, egg-grown, quadrivalent, inactivated influenza vaccine (IIV4) durin

129 ed directly with a standard-dose, egg-grown, quadrivalent-inactivated influenza vaccine (IIV4) for im

130 Cell-based quadrivalent-inactivated influenza vaccine has been show

131 ine effectiveness than traditional egg-based quadrivalent-inactivated influenza vaccine.

132 or higher than those achieved with licensed quadrivalent influenza (standard or high dose) and SARS-

133 mercial controls when formulated with common quadrivalent influenza antigens.

134 -34.2 to 8.37), and ChAdOx1 plus recombinant quadrivalent influenza vaccine (2.53%, -13.3 to 18.3).

135 5% CI -14.7 to 12.1), BNT162b2 plus cellular quadrivalent influenza vaccine (6.17%, -6.27 to 18.6), B

136 dy 2, performed with an egg-grown adjuvanted quadrivalent influenza vaccine (aQIVe) using egg-grown t

137 The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improv

138 ine (modRNA group) or a licensed inactivated quadrivalent influenza vaccine (control group) during th

139 VE) of ccIIV4 versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing inf

140 ted co-administration of adjuvanted seasonal quadrivalent influenza vaccine (FLU-aQIV) and respirator

141 eF3), was co-administered with a single-dose quadrivalent influenza vaccine (FLU-D-QIV) in a phase 3,

142 eF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine (FLU-QIV) in older adults

143 ency in vivo in BALB/c mice with inactivated quadrivalent influenza vaccine (QIV) and tested the cell

144 lar (IM) injection of commercially available quadrivalent influenza vaccine (QIV) containing A/Singap

145 ated the efficacy of a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B l

146 We assessed a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B l

147 cT(FH) responses to the 2017-18 inactivated quadrivalent influenza vaccine (QIV) in men living with

148 the relative effectiveness of the high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-

149 luenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) in this prespeci

150 r cohorts, as follows: ChAdOx1 plus cellular quadrivalent influenza vaccine (risk difference for infl

151 to vaccinate all residents with recombinant quadrivalent influenza vaccine (RIV4) or standard egg-ba

152 ompared to a 2-dose regimen of standard-dose quadrivalent influenza vaccine (SD-QIV) in pediatric all

153 re immunogenic than 2 doses of standard-dose quadrivalent influenza vaccine (SD-QIV).

154 influenza-strains contained in the seasonal quadrivalent influenza vaccine 2019/2020, as well as SAR

155 3%, -5.44 to 26.0; BNT162b2 plus recombinant quadrivalent influenza vaccine 6.75%, -11.8 to 25.3).

156 ized to high-dose trivalent or standard-dose quadrivalent influenza vaccine and revaccinated for up t

157 immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate (QIV) versus tr

158 h-dose trivalent compared with standard-dose quadrivalent influenza vaccine did not significantly red

159 The VE of inactivated quadrivalent influenza vaccine for preventing hospitaliz

160 alent Influenza Vaccine Versus Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-B

161 ial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted fro

162 n-Indigenous Australians vaccinated with the quadrivalent influenza vaccine into the Looking into InF

163 anish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine Versus Standard-Dose Quad

164 was validated in a licensed vaccine setting (quadrivalent influenza vaccine) and an experimental trim

165 horts, as follows: 129 ChAdOx1 plus cellular quadrivalent influenza vaccine, 139 BNT162b2 plus cellul

166 nfluenza vaccine, 139 BNT162b2 plus cellular quadrivalent influenza vaccine, 146 ChAdOx1 plus MF59C a

167 luenza vaccine, 128 ChAdOx1 plus recombinant quadrivalent influenza vaccine, and 58 BNT162b2 plus rec

168 ups of NHPs received two doses of a seasonal quadrivalent influenza vaccine, followed by sequential i

169 za vaccine, and 58 BNT162b2 plus recombinant quadrivalent influenza vaccine.

170 unlike in control participants who received quadrivalent influenza vaccine.

171 Vax (with or without additional vaccines) or quadrivalent influenza vaccine.

172 time on MF59 adjuvanted seasonal cell-based quadrivalent influenza vaccines (aQIVc) under stressed c

173 The effectiveness of standard, egg-derived quadrivalent influenza vaccines (IIV4) may be reduced in

174 In a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personn

175 Since 2013, quadrivalent influenza vaccines containing 2 B viruses g

176 display the four haemagglutinins of licensed quadrivalent influenza vaccines elicited antibody respon

177 comparison of recombinant versus inactivated quadrivalent influenza vaccines in 18-49 year old adults

178 were equivalent to or better than commercial quadrivalent influenza vaccines, and simultaneously indu

179 t a surprising natural design to achieve the quadrivalent inhibition of translation through a highly

180 To investigate this, quadrivalent LAIV was administered to ferrets 3 days bef

181 ts ages >/=6 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) a

182 IV vaccine delivered intramuscularly and the quadrivalent live-attenuated influenza virus (LAIV) vacc

183 f a first-dose monovalent (varicella [V]) or quadrivalent (measles-mumps-rubella-varicella [MMRV]) fo

184 A quadrivalent meningococcal conjugate vaccine (MCV-4) is

185 A quadrivalent meningococcal conjugate vaccine (MCV4) was

186 red to as NVX), a half dose of NVX, ChAd, or quadrivalent meningococcal conjugate vaccine (MenACWY)co

187 Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT

188 n Practices now recommends immunization with quadrivalent meningococcal conjugate vaccine for all pre

189 live attenuated influenza virus vaccine and quadrivalent meningococcal conjugate vaccine for use in

190 e vaccination of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in accordan

191 Students at participating schools received quadrivalent meningococcal conjugate vaccine that uses d

192 One dose of quadrivalent meningococcal conjugate vaccine was adminis

193 When compared with a licensed, quadrivalent meningococcal conjugate vaccine, and given

194 nt inactivated influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).

195 Use of the quadrivalent meningococcal vaccine for control of outbre

196 influenza vaccine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37;

197 events were reported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) wom

198 d influenza were first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the

199 group and 1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed u

200 njection site was more common in women given quadrivalent meningococcal vaccine than in those given t

201 r trivalent inactivated influenza vaccine or quadrivalent meningococcal vaccine.

202 Unlike that for serogroups prevented by quadrivalent meningococcal vaccines, public health respo

203 ctogenicity, and humoral immunogenicity of a quadrivalent messenger RNA (mRNA) vaccine against season

204 allocated to receive 2017-2018 standard-dose quadrivalent, MF59-adjuvanted trivalent, high-dose triva

205 st-utility of a first-dose monovalent (V) or quadrivalent (MMRV) followed by a second-dose quadrivale

206 uadrivalent (MMRV) followed by a second-dose quadrivalent (MMRV) UVV programmes.

207 cine strategies utilizing monovalent (V) and quadrivalent (MMRV) vaccines were evaluated for each reg

208 ages of 18 and 64 years to receive either a quadrivalent modRNA influenza vaccine (modRNA group) or

209 h-dose trivalent (n = 2630) or standard-dose quadrivalent (n = 2630) inactivated influenza vaccine an

210 )-adjuvanted, recombinant hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV).

211 vaccinated patients had received Fluarix(R) Quadrivalent or Fluzone(R) Quadrivalent IIV4, respective

212 -dose recombinant influenza vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vacc

213 c segregation distortion, mixed bivalent and quadrivalent pairing in meiosis, and incomplete informat

214 ere, we tested the ability of an attenuated, quadrivalent panfilovirus VesiculoVax vaccine (rVSV-Filo

215 year after vaccination with either PsA-TT or quadrivalent polysaccharide vaccine (PsACWY) from a rand

216 d with the group A component of the licensed quadrivalent polysaccharide vaccine (PsACWY).

217 Use of the currently available quadrivalent polysaccharide vaccine among college studen

218 A quadrivalent precursor to the pentavalent rotavirus vacc

219 olecule biochemistry reveal an unprecedented quadrivalent recognition that ensures simultaneous reado

220 A new quadrivalent recombinant influenza vaccine (RIV4) was co

221 inactivated influenza vaccine [IIV3-HD], or quadrivalent recombinant influenza vaccine [RIV4]), safe

222 e inactivated influenza vaccine [IIV3-HD] or quadrivalent recombinant influenza vaccine [RIV4]), safe

223 Adult studies have shown that quadrivalent recombinant influenza vaccines (RIV4) induc

224 Quadrivalent recombinant influenza vaccines contain thre

225 f the risks associated with HPV, Gardasil, a quadrivalent recombinant vaccine, was developed by Merck

226 the protective efficacy in older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with

227 sed SD quadrivalent (cIIV4), and recombinant quadrivalent (RIV4) influenza vaccines.

228 ivalent (HD-TIV) to 2 doses of standard-dose quadrivalent (SD-QIV) influenza vaccine administered 1 m

229 t (HZ/su) vaccine when coadministered with a quadrivalent seasonal inactivated influenza vaccine (IIV

230 1083 plus placebo or coadministered licensed quadrivalent seasonal influenza (>=65 years: high-dose q

231 cine (eIIV4), cell culture-based inactivated quadrivalent seasonal influenza vaccine (ccIIV4), and re

232 Egg-based inactivated quadrivalent seasonal influenza vaccine (eIIV4), cell cu

233 ), and recombinant haemagglutinin (HA)-based quadrivalent seasonal influenza vaccine (RIV4) have been

234 A messenger RNA (mRNA)-based quadrivalent seasonal influenza vaccine, mRNA-1010, was

235 ve of pre-existing immunity conferred by the quadrivalent seasonal influenza vaccine.

236 In this study, we report on the outcome of quadrivalent third-party VST infusions in 98 recipients

237 We compared the vaccine effectiveness of quadrivalent to trivalent inactivated vaccines (IIV4 to

238 Among those with confirmed doses, quadrivalent types were detected in 0% (95% CI, 0%-7.7%;

239 The quadrivalent (types 6, 11, 16, and 18) human papillomavi

240 ent, high-dose trivalent, and recombinant-HA quadrivalent vaccination.

241 nicity of 2D vs 3-dose (3D) schedules of the quadrivalent vaccine (4vHPV) up to 10 years after the fi

242 Most vaccine used through 2014 was quadrivalent vaccine (4vHPV), which prevents HPV-6, -11,

243 ociations between vaccination (>=1 dose) and quadrivalent vaccine (4vHPV)-type prevalence adjusting f

244 n 2014, prevents 4 HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-

245 We report on the safety of a quadrivalent vaccine (active against HPV types 6, 11, 16

246 NA vaccines were evaluated pre-clinically: a quadrivalent vaccine (BNT166a; encoding the MPXV antigen

247 who received dose 1 (pupil controls) of the quadrivalent vaccine (Gardasil) and their parents/guardi

248 the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6, -11, -16, and -18) will be

249 timate the cost-effectiveness of HPV9 versus quadrivalent vaccine (HPV4), assuming lifelong vaccine p

250 nificantly more effective than the egg-based quadrivalent vaccine (RVE, 2.5%; 95% CI, -2.4% to 7.3%).

251 ons, an antistaphylococcal, biofilm-specific quadrivalent vaccine against an osteomyelitis model in r

252 PV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measura

253 A quadrivalent vaccine combining measles, mumps, rubella,

254 Four VP7 serotypes were incorporated into a quadrivalent vaccine comprised of three rhesus-human rot

255 alent vaccine containing HPV 16 and 18 and a quadrivalent vaccine containing HPV 6, 11, 16, and 18 an

256 za vaccine was not superior to standard-dose quadrivalent vaccine for reducing these events in patien

257 patient-years), whereas in the standard-dose quadrivalent vaccine group, there were 924 primary outco

258 antigens were delivered simultaneously as a quadrivalent vaccine in order to compensate for this var

259 d immunogenicity of the human papillomavirus quadrivalent vaccine in people with HIV have started enr

260 nical trial of rhesus monkey rotavirus-based quadrivalent vaccine in Venezuela, 2207 infants received

261 uestions about the added benefits of using a quadrivalent vaccine instead of a trivalent vaccine.

262 anted NmCV-5, alum-adjuvanted NmCV-5, or the quadrivalent vaccine MenACWY-D, administered intramuscul

263 a single intramuscular dose of NmCV-5 or the quadrivalent vaccine MenACWY-D.

264 iew summarizes the guidelines for use of the quadrivalent vaccine published by the Advisory Committee

265 Despite moving to a quadrivalent vaccine to include strains from both the B/

266 ic upregulated antigen was combined with the quadrivalent vaccine to remove the need for antibiotic t

267 umulative incidence and persistence with >=1 quadrivalent vaccine type (HPV 6/11/16/18) between vacci

268 Age-adjusted detection rates for quadrivalent vaccine types (HPV-6, HPV-11, HPV-16, and H

269 higher incidence in >/=1 city: the group of quadrivalent vaccine types, HPV-45, and HPV-11.

270 et only 8.5% had evidence of exposure to all quadrivalent vaccine types.

271 The cell-cultured quadrivalent vaccine was not significantly more effectiv

272 The HPV types included in the quadrivalent vaccine were detected in 1002 (14.8%) speci

273 A quadrivalent vaccine with O antigens from S. sonnei, S.

274 One of the vaccines (a quadrivalent vaccine) also prevents two HPV types associ

275 PV types 6, 11, 16, and 18 (HPV types in the quadrivalent vaccine) among 4303 persons aged 14-59 year

276 F59C adjuvanted or a cellular or recombinant quadrivalent vaccine).

277 ed States of all 4 HPV types targeted by the quadrivalent vaccine, and its findings can inform vaccin

278 roduction system that is also used for their quadrivalent vaccine, is the first second-generation HPV

279 t respiratory papillomatosis by means of the quadrivalent vaccine, the duration of immunity, and futu

280 Prevalence of quadrivalent vaccine-targeted HPV types (6, 11, 16, 18)

281 Quadrivalent vaccine-type HPV was detected in anal or or

282 t tested positive for all 4 HPV types in the quadrivalent vaccine.

283 CI, 92.0%-100%) after administration of the quadrivalent vaccine.

284 e egg-based IIV for 3 of the 4 components of quadrivalent vaccine.

285 effectiveness (rVE) of ccIIV4 vs egg-derived quadrivalent vaccines (egg-derived IIV4) for that season

286 illness, despite the higher effectiveness of quadrivalent vaccines against the added B virus lineage.

287 ost-effective compared with the bivalent and quadrivalent vaccines at any coverage despite the greate

288 to question the equivalence of trivalent and quadrivalent vaccines in preventing severe influenza B.

289 cell-cultured vaccines relative to egg-based quadrivalent vaccines was 10% (95% confidence interval [

290 marginally more effective than the egg-based quadrivalent vaccines.

291 vaccines were more effective than egg-based quadrivalent vaccines.

292 e slightly more effective than the egg-based quadrivalent vaccines.

293 oid vaccine (Ty21a; PaxVax, London, UK), and quadrivalent virus-like particle HPV vaccine (Merck, Rah

294 per day taken for three alternate days), and quadrivalent virus-like particle human papillomavirus (H

295 A quadrivalent WC3 reassortant vaccine with components of